Han Bo, Gao Zhi-Di, Wang Hai-Xia, Wang Zhao-Hui, Fan Chuan-Bo, Liu Jun-Ling, Tian Meng, Zhao Hong-Guo
Department of Hemotology, Qingdao Hiser Hospital Affiliated to Qingdao University, Qingdao 266033, Shandong Province, China.
Department of Oncology, Qingdao Hiser Hospital Affiliated to Qingdao University, Qingdao 266033, Shandong Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):445-451. doi: 10.19746/j.cnki.issn.1009-2137.2019.02.022.
To investigate the expression of miR-155 in patients with diffuse large B-cell lymphoma (DLBCL), and to explore the effect of transfection of miR-155 inhibitor on the biological characteristics of DLBCL cells.
A total of 76 patients with DLBCL treated in our hospital were selected from April 2013 to December 2017. In the same time, 40 cases of lymph node reactive hyperplasia (LNRH) were selected as control group. DB cells were cultured and divided into miR-155 inhibitor, negative control and blank groups. The expressions of miR-155 in DLBCL, negative and blank control groups were detected by using real-time PCR, the cell proliferation was detected by MTT assay, the apoptosis was detected by flow cytometry, and the cell migration and invasion were detected by Transwell assay.
The relative expression level of miR-155 in tissues of DLBCL patients was significantly higher than that in tissne of controls (1.93±0.16 vs 1.01±0.09) (t=33.991, P=0.000). The expression level of miR-155 increased (P＜0.05) in DLBCL patients with LDH level abnormarity, BCL-2, MUM1, Ki-67≥50%, non-GC type, Ann Arbor stage III-IV, extranodal lesion number≥2 and IPI score 3-5. The relative expression level of miR-155 in the miR-155 inhibitor group was lower than that in the negative control group and the blank group (P＜0.05). The absorbance (A) values at 24, 48, 72 and 96 h of culture in the miR-155 inhibitor group were lower than those in the negative control group and the blank group (P＜0.05), while the apoptotic rate was higher than that in the negative control group and the blank group (P＜0.05). Both the migrating cells and invading cell number in the miR-155 inhibitor group were lower than those in the negative control group and the blank group (P＜0.05).
The miR-155 highly expresses in DLBCL tissue, which relates with tumor malignancy and invasion progression. The specific inhibition of miR-155 expression in DB cells can reduce cell proliferation, accelerate cell apoptosis, and inhibit cell migration and invasion.
研究miR-155在弥漫性大B细胞淋巴瘤（DLBCL）患者中的表达情况，并探讨转染miR-155抑制剂对DLBCL细胞生物学特性的影响。
选取2013年4月至2017年12月在我院治疗的76例DLBCL患者。同时，选取40例淋巴结反应性增生（LNRH）患者作为对照组。培养DB细胞并分为miR-155抑制剂组、阴性对照组和空白组。采用实时荧光定量PCR检测DLBCL组、阴性对照组和空白对照组中miR-155的表达，采用MTT法检测细胞增殖，采用流式细胞术检测细胞凋亡，采用Transwell法检测细胞迁移和侵袭。
DLBCL患者组织中miR-155的相对表达水平显著高于对照组组织（1.93±0.16 vs 1.01±0.09）（t=33.991，P=0.000）。LDH水平异常、BCL-2、MUM1、Ki-67≥50%、非生发中心型、Ann Arbor分期III-IV期、结外病变数≥2个及国际预后指数（IPI）评分3-5分的DLBCL患者中miR-155表达水平升高（P＜0.05）。miR-155抑制剂组中miR-155的相对表达水平低于阴性对照组和空白组（P＜0.05）。miR-155抑制剂组在培养24、48、72和96 h时的吸光度（A）值低于阴性对照组和空白组（P＜0.05），而凋亡率高于阴性对照组和空白组（P＜0.05）。miR-155抑制剂组的迁移细胞数和侵袭细胞数均低于阴性对照组和空白组（P＜0.05）。
miR-155在DLBCL组织中高表达，与肿瘤恶性程度及侵袭进展相关。特异性抑制DB细胞中miR-155的表达可降低细胞增殖，加速细胞凋亡，并抑制细胞迁移和侵袭。
